dndi business v14dndi business plan 2007-2014, executive summary i]z xjggzci edgi[da^d xdciv^ch...
Post on 25-May-2020
2 Views
Preview:
TRANSCRIPT
The revision of the business plan, with methodological support and coaching by Ernst & Young, was prepared over a period of 8 months with extensive internal & external consultation, and 4 workshops. The plan, which has been reviewed once by the Board of Directors (December 2006) and twice by its Executive Committee (November 2006, March 2007), was approved by the Board of Directors in July 2007.
DN
Di B
usin
ess
Pla
n 20
07-2
014
Con
tent
s
DN
Di B
usin
ess
Pla
n 20
07-2
014
Exe
cutiv
e S
umm
ary
DN
Di B
usin
ess
Pla
n 20
07-2
014
Exe
cutiv
e S
umm
ary
DN
Di B
usin
ess
Pla
n 20
07-2
014
Exe
cutiv
e S
umm
ary
DN
Di B
usin
ess
Pla
n 20
07-2
014
DN
Di i
n 20
07
DN
Di B
usin
ess
Pla
n 20
07-2
014
DiscoveryS LS LO
Pre-clinical Clinical Available to patients
DHFR inhibitors, LT FDC Artesunate-Amodiaquine, M
FDC Artesunate-Mefloquine, M
Nifurtimox-Eflomithine, H
Paromomycin, VL
Imiquimod, CL
AmBisome, L
Drug combinations, VL
Ravuconazole, C
Amphotericin B polymer, VL
NPC1161B, an 8-aminoquinoline, VL
CP inhibitors,T
TR inhibitors, LT
Microtubuleinhibitors, H
Novelnitrohetero-cycles, H
Ascofura-none, H
Scynexisscreening, T
CDRIscreening, T
Genzymescreening, T
Kitasatoscreening, T
Nitroimidazoles 2, LT Nitroimidazoles 1, H
L: Leishmaniasis VL: Visceral leishmaniasis CL: Cutaneous leishmaniasisT: Trypanosomiasis C: Chagas disease H: Human African trypanosomiasisM: Malaria
DN
Di i
n 20
07
DN
Di B
usin
ess
Pla
n 20
07-2
014
DN
Di i
n 20
07
DN
Di B
usin
ess
Pla
n 20
07-2
014
DN
Di i
n 20
07
DN
Di B
usin
ess
Pla
n 20
07-2
014
The
land
scap
e of
rese
arch
and
dev
elop
men
t for
neg
lect
ed d
isea
ses
3
18
1.3%Tropicaldiseases
Other drugs Tuberculosis1,535
DN
Di B
usin
ess
Pla
n 20
07-2
014
The
land
scap
e of
rese
arch
and
dev
elop
men
t for
neg
lect
ed d
isea
ses
A
A
B
C
A - Global Diseases
C
Z
C - Most Neglected
B - Neglected
World Pharmaceutical Market, > 600 billion USD in 2005
Z
B
se ses include cancer, as well as cardiovascular, metabolic, bone and joint diseases; affect people around the world; and constitute the main focus of the R&D-based pharmaceutical industry.
eg e ted se ses such as malaria and tuberculosis, primarily affect people in poor countries but secondarily affect people in industrialized countries (e.g. people who contract malaria while travelling). Therefore, a small market exists, as do some R&D efforts.
st eg e ted se ses include human African trypanosomiasis (also known as sleeping sickness), South American trypanosomiasis (also known as Chagas disease), Buruli ulcer, dengue fever, leishmaniasis, leprosy, lymphatic filariasis, and schistosomiasis. These diseases predominate in developing countries, where people are too poor to pay for any kind of treatment and do not represent a viable market. Therefore, these diseases fall outside the scope of the drug industry's R&D efforts.
he gre sh ded re represents the part of the pharmaceutical market for products addressing life-style conditions that are not purely disease based (such as male pattern baldness, stress and jet-lag), which nonetheless represent a highly profitable market segment in wealthy countries.
DN
Di B
usin
ess
Pla
n 20
07-2
014
The
land
scap
e of
rese
arch
and
dev
elop
men
t for
neg
lect
ed d
isea
ses
DN
Di B
usin
ess
Pla
n 20
07-2
014
The
land
scap
e of
rese
arch
and
dev
elop
men
t for
neg
lect
ed d
isea
ses
DN
Di B
usin
ess
Pla
n 20
07-2
014
The
land
scap
e of
rese
arch
and
dev
elop
men
t for
neg
lect
ed d
isea
ses
DN
Di B
usin
ess
Plan
200
7-20
14Th
e la
ndsc
ape
of re
sear
ch a
nd d
evel
opm
ent f
or n
egle
cted
dise
ases
DN
Di B
usin
ess
Plan
200
7-20
14Th
e la
ndsc
ape
of re
sear
ch a
nd d
evel
opm
ent f
or n
egle
cted
dise
ases
DN
Di B
usin
ess
Plan
200
7-20
14D
ND
i bus
ines
s m
odel
DN
Di B
usin
ess
Plan
200
7-20
14D
ND
i bus
ines
s m
odel
DN
Di B
usin
ess
Plan
200
7-20
14D
ND
i bus
ines
s m
odel
DN
Di B
usin
ess
Plan
200
7-20
14D
ND
i bus
ines
s m
odel
DN
Di B
usin
ess
Plan
200
7-20
14D
ND
i bus
ines
s m
odel
DN
Di B
usin
ess
Plan
200
7-20
14D
ND
i bus
ines
s m
odel
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14R&
D S
trate
gy
DN
Di B
usin
ess
Plan
200
7-20
14O
rgan
isatio
n &
Gov
erna
nce
DN
Di B
usin
ess
Plan
200
7-20
14O
rgan
isatio
n &
Gov
erna
nce
DN
Di B
usin
ess
Plan
200
7-20
14O
rgan
isatio
n &
Gov
erna
nce
DN
Di B
usin
ess
Plan
200
7-20
14O
rgan
isatio
n &
Gov
erna
nce
DN
Di B
usin
ess
Plan
200
7-20
14Ex
pend
iture
s
DN
Di B
usin
ess
Plan
200
7-20
14
,1
%
3 %
35%
3%
%
1 %
u a eouseis a iasis
alaria
a as
isceraleis a iasis
era olo ies
T
Expe
nditu
res
enditure breakdo n b D stage, 200 20
2
2Clinical
C C
reclinical
mplementation
Screening & ead ptimization
DN
Di B
usin
ess
Plan
200
7-20
14Ex
pend
iture
s
100
eneral anagement
undraising
R&D Cost
Strengthening Capacities
Advocacy
5
DN
Di B
usin
ess
Plan
200
7-20
14Ex
pend
iture
s
DN
Di B
usin
ess
Plan
200
7-20
14Ex
pend
iture
s
DN
Di B
usin
ess
Plan
200
7-20
14Ex
pend
iture
s
DN
Di B
usin
ess
Plan
200
7-20
14Ex
pend
iture
s
DN
Di B
usin
ess
Plan
200
7-20
14Re
sour
ces
DN
Di B
usin
ess
Plan
200
7-20
14
46%
51%
ublicnstitutional
oundingartners
oundations & arge Donors 3%
Reso
urce
s
DN
Di B
usin
ess
Plan
200
7-20
14Re
sour
ces
DN
Di B
usin
ess
Plan
200
7-20
14Re
sour
ces
DN
Di B
usin
ess
Plan
200
7-20
14
2
5
ou da io sa or o ors
ublics i u io al
e eralublic
ou diar ers
Reso
urce
s
@
top related